Agendia Expands its Business Activities in Germany

The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows MammaPrint is the only test on the German market supported by the highest level of medical evidence (1A) IRVINE, … Continued

Agendia Responds to “Clinical Insights on MINDACT”

  Dear Dr. Febbo, I recently received an email from you, in which you provided your unsolicited “Clinical Insights on MINDACT”.  I have been a practicing medical oncologist for nearly 30 years, the last 20 of which have been devoted … Continued

New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint® in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy

46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® and MINDACT shows could possibly … Continued